TABLE 1.
Ig | Visit | Antibody titer (AUC)b |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Vaccine prime gp120, 92TH023 gp120c | Vaccine boost gp120 |
HIV-1 gp140 |
CD4bsd | V3 peptidese |
C1 peptidee |
|||||||
A244 gp120c | MN gp120c | 1086 clade C gp140 | Consensus gp140 | V3 107 C | V3 B | V3 C | C1 BC | C1 AE | ||||
IgG | 1 | <100 | <100 | <100 | <100 | <100 | <100 | 543 | 314 | 153.8 | 325 | <100 |
8 | 4,168 | 4,606 | 29,300 | 30,633 | 15,769 | <100 | 440 | 6,347 | 3,806 | 1,978 | 2,192 | |
IgA | 1 | <100 | <100 | <100 | <100 | <100 | <100 | 194 | <100 | <100 | <100 | <100 |
8 | 106 | <100 | 1,635 | 566 | 185 | <100 | 182 | 188 | 122 | <100 | <100 |
Circulating plasma HIV-1-specific antibody binding titers to HIV-1 envelope proteins and peptides were measured by binding antibody multiplex assay. Antibody titers, calculated as area under the curve (AUC), are shown for HIV-specific IgG and IgA at prevaccination visit 1 and 2 weeks after the last vaccination (visit 8). Data are representative of two independent experiments.
Visit 8 AUC values 3-fold greater than visit 1 values are in bold, and negative values of <100 are in italic.
Env proteins contain the HIV-1 sequence without herpesvirus gD (75).
CD4bs specificity was tested by differential binding to YU2 old core/YU2 old core D368R and RSC3/RSC3 delta 371 (76).
Subtypes A, B, and C are noted.